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Introduction
Metabolic disorders, ascribable to enzyme deficiency or dysfunction (especially 
cofactor deficiency), lead to either excess or lack of special metabolic components 
(1). These inherited metabolic diseases are mostly revealed during infancy or 
neonatal ages; however, they can occur at any age, even in adulthood. Genetic 
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most prevalent form of this metabolic disorder. The frequency of consanguinity 
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necessarily has to be present for an individual to have 
a metabolic disorder. More importantly, early diagnosis 
and establishment of appropriate treatment strategies 
can help to prevent the developmental regression and 
mental retardation. Paraclinical findings including 
metabolic acidosis, mild or moderate hyperammonemia, 
ketosis, sepsis-like conditions, bone marrow suppression 
(11-13), hypoglycemia, hepatic failure, and secondary 
carnitine deficiency can also help to diagnose the process 
(13). Diagnosis could be verified through measurement 
of plasma amino acids as well as the analysis of enzymes 
and organic acids in urine (14). Unless screening 
methods are employed, subclinical forms of organic 
acidemia might be undiagnosed. 
Metabolic screening for inherited diseases is not 
implemented in Middle East countries; however, these 
diseases are more prevalent in these regions (15). 
This study aimed to evaluate some of the demographic 
and clinical findings in pediatric patients affected by 
organic acidemia.
Materials & Methods
This cross-sectional study was part of a larger study 
conducted on patients with metabolic disorders during 
a period of 7 years (2007 to 2014) in Isfahan Province, 
central Iran. Our study covered a wide range of cases 
from newborn infants (age, one week) to 17-yr-old 
adolescents. Demographic information, history of 
disease, developmental and educational status, clinical 
and general conditions were obtained from hospitalized 
records in children’s hospitals (Imam Hussain, Azzahra, 
Amin) in Isfahan, Iran, known as third level referral 
centers and metabolic disorder centers in Isfahan 
Province. Information of supplementary questionnaire 
designed for this purpose was collected through 
phone and in-person interview by assistant professor 
of endocrinology and metabolic diseases and trained 
nurses. 
Enzymatic and metabolic evaluation of patients’ blood 
was conducted at the Wagner Stibbe Laboratory in 
Hanover, Germany. Exclusion criteria were lack of 
compliance, lack of parental consent, and uncertain 
paraclinical features. Incidence (Incidence proportion) 
was estimated based on the Meikle et al., method 
by dividing the number of live births (n = 602,259) 
defects can result in either catabolism or abnormal 
anabolism of proteins, carbohydrates, lipids, and other 
complex molecules (2). These diseases are generally 
attributed to default of enzymes constituting metabolic 
pathways. Genetic defects lead to accumulation of 
abnormal biochemical substrates that may potentially be 
toxic. Furthermore, these inherited disorders may result 
in an excess of biomaterials that do not occur in normal 
conditions and the body is unable to metabolize (2, 3). 
Metabolic disorders have a wide range of clinical 
symptoms. The prevalence of metabolic diseases varies 
in accordance with study population characteristics such 
as race, ethnic structures, or screening programs (4). 
Different organs may be involved in metabolic disorders 
and simultaneously show pathological dysfunction. 
Males and females have an equal likelihood of disease 
in autosomal either dominant or recessive forms. In 
fact, onset of disease may vary due to environmental 
factors and the nature of disease. Usually, newborn 
infants appear healthy at birth but clinical symptoms 
are developed later in life. More importantly, those of 
earlier symptoms in life, experience more acute form of 
the disease (5). 
Metabolic disorders are commonly categorized as 
autosomal recessive form of metabolic disorders (6); 
for this reason, the history of an infant (sudden death, 
parental consanguinity) can be used to provide clues of 
the presence of such a disorder. These diseases potentially 
cause damage to vital organs (especially the brain) unless 
proper treatment is started early. Therefore, screening 
methods facilitating early diagnosis of metabolic 
diseases can preclude progressive neurological disorders 
and clinical manifestations that may lead to death (5).
Organic acidemia is classified into five categories as 
follows (7-10):
1) Branched-chain organic acidemia 
2) Multiple carboxylase deficiency, including 
holocarboxylase synthetase deficiency and biotinidase 
deficiency
3) Glutaric aciduria type I
4) Fatty acid oxidation defects 
5) Disorders of energy metabolism
During infancy, threatening signs such as lethargy, poor 
feeding, and vomiting may develop because of one of 
these disorders; however, none of these clinical signs 
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manifestations were found in most of the cases between 
the ages of one month and one year (50.5%). Onset 
of clinical signs in isovaleric acidemia and PA/MMA 
occurred most regularly in neonates (83.3%) and in 
infancy, respectively (65.5%). Furthermore, isovaleric 
acidemia was much more frequently diagnosed within 
the neonatal period (33.3%).
Lethargy and tachypnea are the most prevalent symptoms 
of metabolic disorders. Most patients are affected by 
acidosis, and one third of them suffered from convulsions 
and developmental disorders. Hyperammonemia was 
more frequently found in PA/MMA patients (Figure 1, 
Table 2). 
A minority of patients (9.7%) were studying in ordinary 
schools; the remainder were either studying in special 
schools for children with various disabilities or could not 
go to school. 
A history of infant mortality was found in 12.2% of 
the families suffering from organic acidemia. Most of 
these mortalities occurred due to the lack of multiple 
carboxylase and biotinidase. 22.3% of mothers whose 
their children were affected by organic acidemia had 
a history of abortion. The mortality rate was 18.8% 
in patients with organic acidemia; one third of the 
population with PA/MAA died. Just about 11% of the 
infants were given special infant formula.
obtained from the Department of Census and Statistics 
in Isfahan Province to the number of diagnosed cases 
for each disease (16). According to the definition of 
marriage, first cousin was included cousin marriage that 
is marriage between people with a common grandparent. 
The study was approved by the Ethical Committee of 
Isfahan University of Medical Sciences. Data were 
analyzed through a descriptive method via SPSS v22 
software (IBM; Armonk, New York, USA). 
Results
Out of 5100 patients screened in this study, 392 patients 
were affected by one of the metabolic disorders and 167 
individuals had organic acidemia (Table 1).
The incidence rate of organic acidemia was 27/100,000 
live births (1/3606 live births in Isfahan Province). 
Propionic acidemia/methyl malonic acidemia (PA/
MMA) were the most prevalent forms of metabolic 
disorders (1/10,383 live births). Organic acidemia was 
more prevalent in men (53.8%) than in women (46.2%). 
The frequency of consanguinity in patients affected by 
this disease was 84.7%. The absolute majority of sufferers 
from these diseases were inpatients (83.9%), while PA/
MMA patients were more frequently hospitalized (more 
than 10 times as frequently according to their medical 
records). 42.6% cases of organic acidemia demonstrated 
tailored clinical signs as neonates, whereas clinical 
Demographic and Clinical Findings in Pediatric Patients Affected by Organic Acidemia
Table 1. Frequency of Organic Acidemia
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Fig 1. Frequency of biochemical findings in organic acidemias
Discussion
In this study, most of the metabolic disorders belonged to 
the organic acidemia group; two-thirds of them resulted 
from consanguinity. Most patients with organic acidemia 
were diagnosed before the first year, whereas in another 
study, half of the cases were diagnosed before the age of 
3 yr (16). 
In contrast to our study, this disease was rarely diagnosed 
in Singapore and Brazil. To elaborate, the mean age 
of diagnosis was during the twenty-third month in 
Brazilian patients; two-thirds of the patients from 
Singapore were between the ages of 1 and 13 yr (17, 18). 
This variety in the age of diagnosis could be ascribed to 
epidemiological factors (especially disease prevalence) 
and clinical manifestations differing in organic acidemia. 
Additionally, the ages at which patients are referred 
for potential diagnosis-and the frequency of timely 
diagnosis-may also differ according to family awareness 
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deaths in the family and consanguinity can be addressed 
as diagnostic keys for metabolic disorders. Metabolic 
diseases are more likely to occur when two recessive 
alleles of autosomal gene transfer due to consanguinity. 
These data were consecutively shown in previous studies, 
conducted in Turkey, Saudi Arabia, Brazil and Iran (17, 
29-31). For example, the rate of consanguinity marriages 
rate was as high as 60% in some societies, providing 
a background for the genetic risk factors of these 
metabolic diseases (30). In Turkey, Stike et al. ascribed 
the increase of metabolic disorders to consanguinity 
(29). In comparison with a previous research conducted 
in Iran, our study showed a higher frequency of parental 
consanguinity in PA/MAA patients (31). 
The clinical signs attributed to organic acidemia, 
however, differed in accordance with the designs of 
different studies and the subgroups of organic acidemia. 
We showed that acidosis was found in half of the cases 
affected by organic acidemia, while one third of these 
patients had some degree of developmental disorders 
and convulsion. In Pakistan, respiratory distress and 
developmental disorder were the most common clinical 
signs (26). In PA/MAA patients, developmental 
disorders, convulsion, hyperammonemia, and acidosis 
were demonstrated in 60%, 15%, and 25% of the cases, 
respectively (31). In comparison to our study, the rate 
of growth retardation in the aforementioned study was 
high (30% to 50%). Recurrent vomiting, lethargy, and 
respiratory distress were the most prevalent clinical 
signs of organic acidemia (27). In Mexico, González 
et al. documented different clinical signs such as 
vomiting, metabolic acidosis, and loss of consciousness 
in MAA patients (32). Organic acidemia cases showed 
neurologic abnormalities, metabolic acidosis, and growth 
retardation in 65%, 42%, and 14% of cases, respectively 
(17). In our study, the rate of growth retardation was 
higher. Nevertheless, Wajner et al. documented a high 
incidence rate of psychomotor retardation in organic 
acidemia patients, which was much more compared to 
our study (17). 
Male/female ratio in organic acidemia patients may differ 
to some extent. For example, the ratios in our study and 
in the Brazilian study were 1:1, while in studies carried 
out in Libya and Pakistan the patient populations were 
primarily composed of men, with male: female ratios 
of the potential for the disease; some families may be 
more aware than others of the potential for metabolic 
disorder in their children. 
The incidence of metabolic disorders differs in many 
parts of the world. In our study, incidence of organic 
acidemia was 27/100,000 live births. These results were 
in accordance with similar earlier trials, where organic 
acidemia was more prevalent in the Middle East; 
however, it was less prevalent in Canada, Australia, 
and Italy (15, 19). To elaborate, in Italy, incidence of 
organic acidemia was 1/21,422 live births when PA/
MMA was the most prevalent subgroup (1/61,775 live 
births) (16). Furthermore, we showed that incidence of 
organic acidemia was 1/3606 while PA/MMA incidence 
was 1/10,383 live births. By comparison, the incidence 
rate of this disease was lower in Italy (13.7%), India 
(41.6%), Netherlands (41.6 %), Singapore (32.3%), and 
Saudi Arabia (20%) and higher in China (50%) (16, 
18, 20-22). Our study showed that PA/MMA were the 
most prevalent forms of organic acidemia, which is in 
accordance with analogous studies conducted in China 
and Saudi Arabia, Pakistan and Egypt (19, 22-25). For 
example, incidence rate of PA/MMA in Saudi Arabia 
and Karachi (Pakistan) was 29% and 62%, respectively 
(19, 26). Importantly, high incidence rates of organic 
acidemia (42%) as well as PA/MAA (23.5%) were 
previously proven in Shiraz, Iran (27). The possibility 
of metabolic diseases significantly increases when 
the patient shows severe clinical symptoms due to the 
common associated microbial infections. The patient 
may suffer from lack of appropriate responses to the 
treatment strategies. Fortunately, early diagnosis and 
treatment of metabolic disorders can significantly 
improve the disease prognosis (28); thus, developed 
countries are implementing selective screening that 
aims to detect special metabolic disorders (27). On the 
other hand, many of the metabolic diseases are more 
dangerous because they cannot be efficiently diagnosed 
due to the lack of patient referral to the pediatric 
metabolic department or to the absence of appropriate 
screening strategies.
Each of the metabolic diseases, as a separate entity, 
is rare; nevertheless, their overall prevalence is 
considerable. Genotypes of these diseases generally 
are autosomal recessive. However, a history of sudden 
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varying among the individual studies (17, 24, 33). In 
particular, men seemed to present to a greater degree 
with metabolic disorders in Libya and Pakistan. 
Our study as well as the study by Wajner et al. documented 
a low mortality rate (20%). On the contrary, mortality 
rates from metabolic disorders in France, Thailand, and 
China were higher (29%, 36%, and 50%, respectively); 
a higher mortality rate was also documented in Mexico 
(17, 32, 34). In a study, multiple carboxylase deficiencies 
had the best outcomes, and all patients treated with 
biotin recovered with no developmental delay, whereas 
mental retardation persisted in the patients with PA and 
MAA despite treatment. All cases with glutaric aciduria 
had developmental delay (23). 
In general, early diagnosis of organic acidemia is 
essential and can potentially prevent irremediable 
disorders. Neonatal screening is crucial since the 
disease’s outcomes are improved when the disease is 
diagnosed as close as possible to its onset. Nevertheless, 
socioeconomic problems impede the delivery of formula 
specialized for patients with organic acidemia; these 
patients are more likely to be affected by physical and 
mental developmental disorders. 
Lack of patient availability and cooperation, especially 
when they could not afford to pay for the paraclinical 
examinations, was assumed as our limitation. 
In conclusion, each of the metabolic diseases, as a 
separate entity, is rare; nevertheless, they are prevalent 
when considered as a group. These diseases could result 
in mental and developmental disorders without quick 
diagnosis and treatment, imposing costs on families 
and on society due to frequent inpatient treatments 
and the need for a specialized formula and (later) diet. 
Furthermore, more mutations should be identified 
in societies affected by consanguinity. However, 
specialized management should be applied not only 
to enhance life expectancy, but also to harness tardy 
signs of metabolic disorders. Additionally, community 
discussions concerning educational promotion should 
be sought through these types of dedicated management 
steps. Further research should also be conducted to 
determine worthwhile and more-efficient screening 
methods as well as long-term neurological prognosis. 
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